Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease - PubMed (original) (raw)
Clinical Trial
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
N C Fox et al. Neurology. 2005.
Abstract
Background: Alzheimer disease (AD) is characterized by progressive cerebral atrophy that may be measured using MRI. Reported are MRI findings of a Phase IIa immunotherapy trial in AD prematurely terminated owing to meningoencephalitis in a subset of patients.
Objective: To assess cerebral volume changes in patients immunized with AN1792 (beta-amyloid [Abeta] 1 to 42) who were antibody responders (anti-AN1792 IgG titer of > or =1:2,200) compared with placebo patients.
Methods: This randomized, multicenter, placebo-controlled, double-blind trial of AN1792 225 mug plus QS-21 50 mug included 372 patients with probable AD. Patients received one to three injections of AN1792/QS-21 or saline and were assessed for 12 months. Volumetric MRI was performed pre dose and at month 12 or early termination. Brain, ventricular, and hippocampal volume changes were measured from registered scan pairs.
Results: Two hundred eighty-eight patients had paired scans (mean interval 10.9 months). Antibody responders (n = 45) had greater brain volume decrease (3.12 +/- 1.98 vs 2.04 +/- 1.74%; p = 0.007), greater ventricular enlargement as a percentage of baseline brain volume (1.10 +/- 0.75 vs 0.48 +/- 0.40%; p < 0.001), and a nonsignificant greater hippocampal volume decrease (3.78 +/- 2.63 vs 2.86 +/- 3.19%; p = 0.124) than placebo patients (n = 57). Increased losses in brain volume were not reflected in worsening cognitive performance; a composite z score across a Neuropsychological Test Battery showed differences favoring antibody responders over placebo (0.03 +/- 0.39 vs -0.24 +/- 0.45; p = 0.008).
Conclusions: A dissociation between brain volume loss and cognitive function was observed in AN1792/QS-21 antibody responders. The reasons for this remain unclear but include the possibility that volume changes were due to amyloid removal and associated cerebral fluid shifts.
Similar articles
- Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team. Gilman S, et al. Neurology. 2005 May 10;64(9):1553-62. doi: 10.1212/01.WNL.0000159740.16984.3C. Neurology. 2005. PMID: 15883316 Clinical Trial. - Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.
Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; AN1792 (QS-21)-251 Study Team. Vellas B, et al. Curr Alzheimer Res. 2009 Apr;6(2):144-51. doi: 10.2174/156720509787602852. Curr Alzheimer Res. 2009. PMID: 19355849 Free PMC article. Clinical Trial. - Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Orgogozo JM, et al. Neurology. 2003 Jul 8;61(1):46-54. doi: 10.1212/01.wnl.0000073623.84147.a8. Neurology. 2003. PMID: 12847155 Clinical Trial. - Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
Ghochikyan A. Ghochikyan A. CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. doi: 10.2174/187152709787847298. CNS Neurol Disord Drug Targets. 2009. PMID: 19355933 Free PMC article. Review. - Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Pride M, et al. Neurodegener Dis. 2008;5(3-4):194-6. doi: 10.1159/000113700. Epub 2008 Mar 6. Neurodegener Dis. 2008. PMID: 18322388 Review.
Cited by
- Molecular Therapeutics in Development to Treat Alzheimer's Disease.
Tartaglia MC, Ingelsson M. Tartaglia MC, et al. Mol Diagn Ther. 2024 Sep 24. doi: 10.1007/s40291-024-00738-6. Online ahead of print. Mol Diagn Ther. 2024. PMID: 39316339 - Overview of ADNI MRI.
Jack CR Jr, Arani A, Borowski BJ, Cash DM, Crawford K, Das SR, DeCarli C, Fletcher E, Fox NC, Gunter JL, Ittyerah R, Harvey DJ, Jahanshad N, Maillard P, Malone IB, Nir TM, Reid RI, Reyes DA, Schwarz CG, Senjem ML, Thomas DL, Thompson PM, Tosun D, Yushkevich PA, Ward CP, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Jack CR Jr, et al. Alzheimers Dement. 2024 Oct;20(10):7350-7360. doi: 10.1002/alz.14166. Epub 2024 Sep 11. Alzheimers Dement. 2024. PMID: 39258539 Free PMC article. Review. - Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC. Jack CR Jr, et al. Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27. Alzheimers Dement. 2024. PMID: 38934362 Free PMC article. - Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials.
Ten Kate M, Barkhof F, Schwarz AJ. Ten Kate M, et al. J Prev Alzheimers Dis. 2024;11(1):38-47. doi: 10.14283/jpad.2023.92. J Prev Alzheimers Dis. 2024. PMID: 38230715 Free PMC article. - Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical